HomeEXECUTIVESDr. Peter Small World-Renowned Scientist Is Appointed at Hype to the Role of CMO

Dr. Peter Small World-Renowned Scientist Is Appointed at Hype to the Role of CMO

Dr. Peter Small is a world-renowned Seatle-based physician and scientist. Today Hyfe, a fast-growing AI Medtech company reports Dr. Small has been appointed to the role of Chief Medical Officer.

Dr. Peter Small, a passionate advocate for improving patient care through innovative digital solutions, has decades of experience in respiratory medicine, applied research, and the provision of high-tech healthcare worldwide. Hyfe is pioneering acoustic epidemiology, using machine learning algorithms to detect cough to allow patients and providers to unobtrusively monitor cough frequency, providing real-time insights into individual and community health. A global expert in infectious diseases, epidemiology, and global health, Dr. Small will help shape the company’s direction in the coming years, forging partnerships with organizations and individuals to validate and deploy the technology to improve human health. He will also help guide Hyfe’s remote clinical trials as well as promote patient empowerment through remote monitoring of symptoms and more.

Dr. Small has a long history of bringing innovation to health care. Early in his career, he was a medical resident and chief medical resident at UCSF at the dawn of the HIV epidemic. He subsequently joined the faculty of Stanford University Medical School. There, Dr. Small was a pioneer in the field of molecular epidemiology, publishing papers that helped to shape the public health response to the resurgence of tuberculosis.

In 2002, Dr. Small was one of the earliest leaders at the Bill and Melinda Gates Foundation, where he developed their tuberculosis strategy, built the foundation’s core partnerships and country programs, and oversaw a large portfolio of vaccine, drug and diagnostic product development and deployment. In 2011, he relocated to India where he established the foundation’s collaborative tuberculosis program. Subsequently, he joined Stony Brook University as the Founding Director of the University-wide Global Health Institute focused on the use of technology to deliver health care in remote Madagascar and Nepal.

Respiratory diseases are among the leading causes of death and disability in the world. WHO statistics reveal that around 334 million people suffer from asthma worldwide, while millions die prematurely every year from tuberculosis, pneumonia, lung cancer, and other respiratory illnesses. Hyfe was founded in 2020 with the objective to build acoustic tools for respiratory diagnostics and monitoring. In just over a year since its launch, the Hyfe platform is used daily by researchers, medical professionals as well as thousands of regular people all over the world.

Hyfe’s technology is built using the world’s largest and fastest growing cough dataset, improved upon continuously via machine learning, and vetted extensively through partnerships with clinical researchers around the world

Commenting on the appointment of Dr. Small as Chief Medical Officer, Hyfe Co-Founder and CEO Joe Brew said:

“We are thrilled to welcome Dr. Peter Small to the team as our CMO. This is a very exciting time for Hyfe, and Peter’s decades of experience developing and deploying innovative health solutions globally make him the perfect fit for our capabilities. With Peter onboard, Hyfe is poised to empower patients and providers to remotely monitor health.”

Commenting on joining the team at Hyfe, Dr. Peter Small said:

“It’s ironic how much people focus on counting steps while ignoring cough, which is far more consequential. Hyfe is a science-driven company with the technology to make cough count. Particularly now, with increased awareness of cough and the rapid growth of digital health driven by Covid-19, this technology can improve the lives of patients, the care provided by doctors, and the efficiency of health systems.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy